摘要
目的应用达拉他韦联合阿舒瑞韦治疗初治的基因1b型慢性丙型肝炎(CHC)患者,观察疗效及其外周血淋巴细胞亚群的变化。方法2022年1月~2024年7月我院收治的65例初始治疗的基因1b型CHC患者,被随机分为对照组32例和观察组33例,分别给予索磷布韦联合达拉他韦治疗或达拉他韦联合阿舒瑞韦治疗3个月。常规检测血清HCV RNA载量,使用流式细胞仪检测外周血淋巴细胞亚群。考核快速病毒学应答(RVR)、治疗结束时病毒学应答(ETVR)和持续病毒学应答(SVR)。结果观察组RVR、ETVR和SVR分别为84.9%、100.0%和100.0%,对照组则分别为84.4%、100.0%和96.9%,两组无显著性差异(P>0.05);在治疗结束时,观察组血清AST和ALT水平分别为(32.5±5.3)U/L和(39.4±5.9)U/L,与对照组【分别为(33.6±6.2)U/L和(40.5±6.3)U/L】比,无显著性差异(P>0.05);观察组外周血CD4+细胞和CD8+细胞百分比及CD4+/CD8+细胞比值分别为(36.4±4.8)%和(24.6±2.4)%及(1.1±0.4),与对照组【分别为(35.2±4.2)%和(24.5±2.5)%及(1.1±0.3)】比,无显著性差异(P>0.05)。结论应用达拉他韦联合阿舒瑞韦治疗初治的基因1b型CHC患者也可获得较为满意的抗病毒效果,还需要长期随访观察。
Objective The aim of this study was to investigate the efficacy of daclatasvir and asunaprevir combination in the treatment of patients with na ve hepatitis C viral genotype 1b-infected chronic hepatitis C(CHC)and changes of peripheral blood lymphocyte subsets.Methods 65na ve patients with HCV genotype 1b-infected CHC were enrolled in our hospital between January 2022 and July 2024,and were randomly assigned to receive sofosbuviranddaclatasvir in 32 patients in control,or to receive asunaprevir and daclatasvir combination in 33 patients in the observation group for 12 weeks.Serum HCV RNA loads were routinely detected,and peripheral blood lymphocyte subsets were determined by FCM.Rapid virological response(RVR),end of treatment virological response(ETVR)and sustained virologicalresponse(SVR)were evaluated.Results RVR,ETVR and SVRin the observation group were 84.9%,100.0%and 100.0%,not significantly different as compared to 84.4%,100.0%and 96.9%in the control(P>0.05);by end of the antiviral regimen,serum AST and ALT levels in the observation group were(32.5±5.3)U/L and(39.4±5.9)U/L,both not significantly different as compared to[(33.6±6.2)U/Land(40.5±6.3)U/L,respectively]in the control(P>0.05);percentages of peripheral bloodCD4+and CD8+cells as well as CD4+/CD8+cell ratio were(36.4±4.8)%and(24.6±2.4)%,and(1.1±0.4),all not significantly different compared to[(35.2±4.2)%,(24.5±2.5)%and(1.1±0.3),respectively]in the control group(P>0.05).Conclusion Daclatasvir and asunaprevir combination in the treatment of na ve patients with HCV genotype 1b-infected CHC is also efficacious,which needs further clinical long-term follow-up.
作者
刘志东
李文松
高震
孙李妍
丁琪
Liu Zhidong;Li Wensong;Gao Zhen(Department of Pharmacy,Liaozhou Central Hospital,Qingdao 266300,Shandong Province,China)
出处
《实用肝脏病杂志》
2025年第5期679-682,共4页
Journal of Practical Hepatology
基金
山东省烟台市科技创新发展计划基础研究类项目(编号:2023JCYJ065)。
关键词
丙型肝炎
达拉他韦
阿舒瑞韦
基因1b型
初始
治疗
Hepatitis C
Daclatasvir
Asunaprevir
Hepatitis C virus genotype 1b
Na ve
Therapy
作者简介
第一作者:刘志东,男,42岁,大学本科,主管药师。E-mail:liuzhidong8888@163.com;通讯作者:丁琪,E-mail:52414551@qq.com。
